Clarinase

Clarinase is a brand of Loratadine and Pseudoephedrine sulfate Long acting \ Non-Sedating Antihistamine \ Decongestant Tablets, and has another brand name called REPETABS.

Description

Each clarinase repetab tablets contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The 2 active components in the coating are quickly liberated; release of the decongestant in the core is delayed for several hours

Inactive Ingredients

maize starch, povidone, magnesium stearate & purified water

Actions

Loratadine is a potent long acting tricyclic antihistamine with peripheral H1-receptor antagonistic activity, Pseudoephedrine sulfate, one of the naturally occurring alkaloids of ephedra and an orally administered vasoconstrictor, produce a gradual but sustained decongestant effect facilitating shrinkage of congested mucosa in upper respiratory areas, The mucus membrane of the respiratory tract is decongested through the action on the sympathetic nerves

Indications and usage

Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus & lacrimation, Clarinase repetabs tablets are recommended when both the antihistaminic properties of loratadine and the decongestant effect of pseudoephedrine sulfate are desired

Dosage and administration

Adults & children 12 years of age and over; one Clarinsae repetab tablet twice a day

Drug interaction: When administered concomitantly with alcohol, loratadine has no potentiating effect as measured by psychomotor performance studies. Increase in plasma concentrations of loratadine have been reported after concomitant use with ketoconazole, erythromycin or cimetidine in controlled clinical trials, but without clinically significant changes (including electrogardiographic), Other drugs known to inhibit hepatic metabolism should be co-administered with caution until defenitive interaction studies can be completed When sympathomimetics are given to patients receiving Mono Amino Oxidase Inhibitors (MAO Inhibitor), hypertensive reactions, including hypertensive crises may occur, The antihypertensive effects of methyldopa, mecamylamine, reserpine & veratrum alkaloids maybe reduced by sympathomimetics, Beta-adrenergic blocking agents may also interact with sympathomimetics , Increase ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of pseudoephedrine absorption, Kaolin decrease it

Drug\Laboratory \ test interactions

Antihistamines should be discontinued approximately 48 hours prior to skin testing procedures since these drugs may prevent or diminish otherwise positive reactions to dermal activity indicators. The in-vitro addition of pseudoephedrine to sera containing the cardiac iso-enzyme MB of serum creatine phosphokinase progressively inhibits the activity of the enzyme, The inhibition becomes complete over 6 hours.

Adverse reactions

During controlled clinical studies with the recommended dosage, the incidence of adverse effects associated with clarinase repetabs tablets was comparable to that of placebo, with the exception of insomnia & dry mouth, both of which were commonly reported, Other reported adverse reactions associated with both clarinase repetabs tablets and placebo included headaches & somnolence Rare adverse reactions in decreasing order of frequency included nervousness, dizzines, fatigue, nausea, abdominal distress, anorexia, thirst, tachycardia, pharyngitis, rhinitis, acne, pruritus, rach, urticaria, arhtralgia, confusion, dysphonia, hyperkinesia, hypoesthesia, decreased libido, paresthesia, tremor, vertigo, flushing, postural hypotension, increase sweating, eye doisorders, earache, tinnitus, taste abnormality, agitation, apathy, depression, euphoria, panoreiria, increased appetite, change in bowel habits, dyspepsia, eructation, hemorrhoids, tongue discolouration, tongue disorders, vomiting, transiet abnormal hepatic function, dehydration, increased weight, hypertension, palpitation, migraine, bronchospasm, coughing, dyspnea, epistaxis, nasal congestion, sneezing, nasal irritation, dysuria, micturition disorder, nocturia, polyuria, urinary retention, asthenia, back pain, leg cramps, malaise & regors. During the marketing of loratadine, alopecia, anaphylaxis, tachycardia, palpitations & abnormal hepatic function have been reported rarely

Contraindications

Clarinase repetab tablets are contraindicated in those who have shown sensitivity or idiosyncrasy to their components, to adrenergic agents or to other drugs of similar chemical structure. Clarinase repetab tablets are also contraindicated in patients receiving MAO Inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.

Precautions

Sympathomimetics should be used in caution with glaucoma, stenosing peptic ulcer, pylorodudenal obstruction, prostatic hypertrophy or bladder neck obstruction, cardiovascular diseasar:كلاريناز